Announcement on Convening the Q3 2026 Performance Briefing
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
(688276)"Changchun Bcht Biotechnology Co."Announcement on Convening the Q3 2026 Performance Briefing
Filed with SSE · Stock code 688276 ·
6ix is reading this filing.
View original source (Shanghai Stock Exchange)Changchun BCHT Biotechnology Co. on 6ix
Story so far
- Announcement on Voluntary Disclosure Regarding the Acceptance of the Clinical Trial Application for the Combination Formulation of Recombinant Human Anti-Respiratory Syncytial Virus (RSV) Monoclonal Antibody Injection
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Announcement on Return of Previously Used Funds Raised for Temporary Working Capital Supplement and Use of a Portion of Idle Funds Raised for Temporary Working Capital Supplement
Earlier from Changchun BCHT Biotechnology
- Announcement on Voluntary Disclosure Regarding the Acceptance of the Clinical Trial Application for the Combination Formulation of Recombinant Human Anti-Respiratory Syncytial Virus (RSV) Monoclonal Antibody Injection
- Semi-annual Report for 2026
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Announcement on Return of Previously Used Funds Raised for Temporary Working Capital Supplement and Use of a Portion of Idle Funds Raised for Temporary Working Capital Supplement
- Announcement on Resolutions of the 2025 Annual General Meeting
Follow Changchun BCHT Biotechnology into a list and get an email when it puts out news.
Follow Changchun BCHT Biotechnology